Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Other: No treatment given

First Posted Date: 2016-01-25

Last Posted Date: 2019-05-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 2302

Registration Number: NCT02662114

Locations: 🇨🇭
Novo Nordisk Investigational Site, St. Gallen, Switzerland

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Dulaglutide
Drug: semaglutide

First Posted Date: 2016-01-06

Last Posted Date: 2019-10-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1201

Registration Number: NCT02648204

Locations: 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: biphasic insulin aspart
Drug: insulin degludec/insulin aspart

First Posted Date: 2016-01-06

Last Posted Date: 2018-09-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 263

Registration Number: NCT02648217

Locations: 🇦🇪
Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates

A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Diabetes

Interventions: Device: DV3316 pen-injector
Device: FlexPen®
Drug: placebo

First Posted Date: 2015-12-10

Last Posted Date: 2018-02-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 150

Registration Number: NCT02627287

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Other: standard antenatal care
Behavioral: lifestyle intervention

First Posted Date: 2015-12-01

Last Posted Date: 2019-02-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 552

Registration Number: NCT02617693

Locations: 🇲🇾
Novo Nordisk Investigational Site, Seremban, Negeri Sembilan, Malaysia

Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

Phase 2

Completed

Conditions: Growth Hormone Disorder
Growth Hormone Deficiency in Children

Interventions: Drug: somapacitan
Drug: Norditropin® FlexPro® pen

First Posted Date: 2015-11-30

Last Posted Date: 2024-11-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 74

Registration Number: NCT02616562

Locations: 🇯🇵
Institute of Science Tokyo Hospital, Tokyo, Japan
🇺🇸
Nemours/AI duPont Hosp-Chld, Wilmington, Delaware, United States
🇺🇸
Goryeb Children's Hospital, Morristown, New Jersey, United States

and more 34 locations

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin aspart
Drug: NNC0143-0406

First Posted Date: 2015-11-24

Last Posted Date: 2017-12-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 48

Registration Number: NCT02612844

Locations: 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria

Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Other: No treatment given

First Posted Date: 2015-11-20

Last Posted Date: 2015-11-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 9999

Registration Number: NCT02608853

Locations: 🇺🇸
Novo Nordisk Clinical Trial Call Center, Princeton, New Jersey, United States

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide
Drug: sitagliptin
Drug: placebo

First Posted Date: 2015-11-18

Last Posted Date: 2022-07-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1864

Registration Number: NCT02607865

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wellingborough, United Kingdom

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: insulin degludec/liraglutide
Drug: insulin degludec
Drug: liraglutide

First Posted Date: 2015-11-18

Last Posted Date: 2021-04-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 819

Registration Number: NCT02607306

Locations: 🇯🇵
Novo Nordisk Investigational Site, Yamato-shi, Kanagawa, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy